Case Studies

2025-08-25

Yeast Protein Expression Case Studies | Pichia pastoris & S. cerevisiae | AtaGenix

Explore real-world yeast protein expression case studies from AtaGenix. Our Pichia pastoris and Saccharomyces cerevisiae platforms deliver high-yield recombinant proteins with proper folding and glycosylation — supporting enzyme production, diagnostic antigen development, and antibody screening applications.

2025-10-13

AtaGenix Custom Proteins Services Enable Breakthrough in Understanding Cholangiocarcinoma Drug Resistance

This study identifies that ROCK2 promotes Pemigatinib resistance in CCA cells via UBA52-mediated DRP1 ubiquitination. AtaGenix provided high-purity custom proteins essential for validating this mechanism.

2025-07-21

AtaGenix Custom rMet Protein Advances Diabetes β-Cell Research

AtaGenix developed high-purity, endotoxin-free recombinant METRNL protein for research teams, uncovering its critical role in preventing β-cell trans-differentiation to α-cells and sustaining islet function, advancing diabetes metabolic stress studies, and offering new therapeutic target insights.

2025-06-20

Custom HSV-1 gB Protein Expression for Subunit Vaccine Research | AtaGenix

AtaGenix provided CHO-expressed HSV-1 glycoprotein B (gB) and its prefusion mutant gB H516P for a subunit vaccine study led by the Chinese Academy of Medical Sciences (Kunming). Both proteins were purified via Ni-NTA chromatography under identical conditions, ensuring matched quality for head-to-head immunogenicity comparison. Validated through ELISpot (IL-2, IFN-γ) and ELISA (gB-specific IgG), the proteins enabled the team to demonstrate that QS-21/CpG ODN-adjuvanted subunit vaccines induce robust cellular immune responses — published in Vaccine (2025, DOI: 10.1016/j.vaccine.2025.127241).

2025-06-20

Custom RMP & IKKβ Proteins Reveal a New Sepsis Therapeutic Target | AtaGenix

Naval Medical University needed matched sets of GST-tagged RMP variants and His-tagged IKKβ to map a novel protein-protein interaction in sepsis inflammation. AtaGenix delivered four E. coli-expressed proteins — including the critical S439A point mutant — enabling SPR, GST-pulldown, and ADP-Glo kinase assays that identified RMP as a negative regulator of NF-κB signaling. Published in Cell Communication and Signaling (2025, DOI: 10.1186/s12964-025-02278-w).

2025-06-20

Custom PRPF19 Protein Enables Ferroptosis Drug Target Discovery in Diabetic Nephropathy | AtaGenix

Researchers at Huazhong University of Science and Technology needed SPR-grade PRPF19 protein to prove that berberine directly binds this E3 ligase — the pivotal experiment for establishing PRPF19 as a druggable target in diabetic nephropathy. AtaGenix delivered high-purity PRPF19 (1.67 mg/mL) that enabled Biacore T200 confirmation of the berberine–PRPF19 interaction, supported by WB and IP validation. Published in Cell Communication and Signaling (2025, DOI: 10.1186/s12964-025-02253-5).

2025-05-30

Custom PgUGT29 Protein & Antibody Enable Saponin Biosynthesis Discovery | AtaGenix

Researchers at Anhui University of Chinese Medicine needed functional recombinant PgUGT29/PgUGT72 proteins and a specific anti-PgUGT29 antibody to identify the enzyme responsible for PD-to-PD3 glycosylation in medicinal saponin biosynthesis. AtaGenix delivered E. coli-expressed, refolded proteins (>95% purity) and validated rabbit polyclonal antibodies. HPLC confirmed PgUGT29 as the C3-glucosyltransferase, while PgUGT72 (negative control) showed no activity. Published in Int J Mol Sci (2025, DOI: 10.3390/ijms26104832).

2025-05-30

Custom IgM-CH Protein & Anti-C5aR Antibody Power Fish Vaccine Adjuvant Discovery | AtaGenix

Researchers at Huazhong Agricultural University needed recombinant grass carp IgM-CH and anti-C5aR antibodies — two reagents that don't exist commercially — to validate complement C5a-CP as a fish vaccine adjuvant. AtaGenix delivered E. coli-expressed IgM-CH (>95% purity, refolded from inclusion bodies) and rabbit anti-C5aR pAbs (validated by flow cytometry and IF). The team demonstrated that C5a-CP enhances IgM+ B cell phagocytosis and achieves 96% relative survival against A. hydrophila and GCRV-II. Published in Fish and Shellfish Immunology (2025, DOI: 10.1016/j.fsi.2025.110415).

2024-11-05

CHO Stable Cell Line: >3 g/L Antibody Titer & Viral Protein Production | AtaGenix

Two CHO stable cell line case studies from AtaGenix. Case 1: A therapeutic antibody program achieved >3 g/L fed-batch titer with sub-nanomolar affinity (KD = 7.36×10⁻¹¹ M), stable expression across passages, and full QC (SDS-PAGE purity, mycoplasma PCR, SPR kinetics). Case 2: A VZV gE viral glycoprotein stable line for vaccine antigen production, demonstrating AtaGenix's platform versatility across antibody and non-antibody targets.

2024-11-05

Bacillus subtilis Expression: Secreted & Intracellular Protein Case Studies | AtaGenix

Two B. subtilis WB800N expression case studies from AtaGenix. Case 1: Secreted Protein A (~85 kDa) via pHT43 vector achieved 20 mg/L yield at >90% purity — protein directed into culture supernatant without cell lysis. Case 2: Intracellular Protein B (~42 kDa) via pHT254 achieved >95% purity at 1 mg/L. Both leveraged the endotoxin-free, GRAS-designated B. subtilis host, demonstrating AtaGenix's flexibility in prokaryotic expression beyond E. coli.

2024-11-05

HLA-I pMHC Tetramer: From E. coli Expression to T-Cell Detection Reagent | AtaGenix

AtaGenix produced custom pMHC tetramers from scratch: HLA-I heavy chain and β2M expressed in E. coli, refolded with target peptide into stable ternary complexes, site-specifically biotinylated via BirA, and assembled with streptavidin into SEC-verified tetramers. The client confirmed functional CD8+ T-cell staining by flow cytometry — demonstrating AtaGenix's end-to-end MHC-peptide complex platform for custom alleles and epitopes not available commercially.

2024-11-05

E. coli Expression Optimization: Solubility, Periplasmic Folding & Inclusion Body Refolding | AtaGenix

Three E. coli expression case studies from AtaGenix. Case 1: Systematic 32-condition optimization (4 strains × temperature × media) shifted an insoluble target to soluble expression, followed by 3C protease His-tag removal for crystallography. Case 2: Periplasmic expression rescued a disulfide-bonded antibody fragment — correctly folded with intact S–S bonds, no refolding required. Case 3: Gradient dialysis refolding recovered enzymatically active protein from obligate inclusion bodies. Together, these cases demonstrate AtaGenix's ability to exhaust the full E. coli toolkit before escalating to costlier eukaryotic systems.